Soleno Therapeutics (SLNO) announced that its Board of Directors has authorized a share repurchase and that it has entered into an Accelerated Share Repurchase Agreement with Jefferies to repurchase $100 million of Soleno’s common stock.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SLNO:
- Soleno Therapeutics: Strong Q3 Performance and Market Potential Justify Buy Rating
- Soleno Therapeutics’ Financial Challenges: Navigating Risks in VYKAT XR Commercialization
- Soleno Therapeutics’ Earnings Call Highlights Growth Amid Challenges
- Midday Fly By: Broader market bought on dip after tech selloff
- Soleno Therapeutics falls -29.0%